A PHASE II, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, DOSE ESCALATION AND DOSE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DYSPORT IN VULVODYMIA PATIENTS

Registry ID

D-FR-52120-236

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

IPSEN BIOPHARMACEUTICALS CANADA INC

Start date

2020-05-15

Last update

2019-11-13

Conditions

• VULVODYNIA

View on source registry